Overview

Clinical Research of Reducing Medication Regimen for Ursodeoxycholic Acid in Treatment of Stable Primary Biliary Cholangitis

Status:
Recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis. The participants will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at different level, while the control group will receive standard dosage of UDCA. The effect of therapy will be evaluated every three months.

Phase:

Phase 4

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Ursodeoxycholic Acid